期刊文献+

加味当归四逆汤治疗0级糖尿病足的疗效及对血清晚期糖基化终产物水平的影响:随机对照试验(英文) 被引量:14

Therapeutic effects of modified Danggui Sini Decoction on plasma level of advanced glycation end products in patients with Wagner grade 0 diabetic foot:a randomized controlled trial
暂未订购
导出
摘要 背景:许多研究证实晚期糖基化终产物(advanced glycation end product,AGE)与糖尿病血管病变密切相关,中医药在该类疾病治疗中存在一定优势。目的:评价加味当归四逆汤治疗Wagner0级糖尿病足患者的临床疗效、安全性及其对血清AGE水平的影响。设计、场所、受试者和干预措施:采用随机、阳性药物对照研究方案。将72例血瘀证、肾阳虚证Wagner0级糖尿病足患者随机分为治疗组和对照组,每组36例,均为广州中医药大学茂名市中医院门诊和住院患者。患者签署知情同意书之前已经被口头或者书面告知研究过程。该研究由广州中医药大学茂名中医院医学伦理委员会批准。治疗组口服加味当归四逆汤,对照组予西药西洛他唑治疗。两组均以14d为1个疗程,连续治疗3个疗程。主要结局指标:观察两组治疗前后临床症状、踝肱指数(ankle-brachial index,ABI)、肌电图、下肢动脉超声多普勒血流动力学指标、空腹血糖、糖基化血红蛋白、纤维蛋白原和AGE水平变化。记录实验室检查结果和不良事件作为安全性评估的依据。结果:治疗组治疗后临床症状、ABI、下肢动脉超声多普勒血流动力学和神经传导速度等指标均较对照组改善,差异有统计学意义(P<0.05,P<0.01)。治疗后两组血清AGE均明显下降,且治疗组与对照组比较,差异亦有统计学意义(P<0.01)。结论:加味当归四逆汤能改善Wagner0级糖尿病足患者的临床症状,并对糖尿病血管病变有一定的治疗作用。 Background: Many studies have demonstrated association between advanced glycation end products (AGEs) and diabetic angiopathy. There are certain advantages of traditional Chinese medicine (TCM) therapy in treatment of these diseases. Objective: To evaluate the therapeutic effects and safety of modified Danggui Sini Decoction, a compound traditional Chinese herbal medicine for nourishing blood to warm meridians, on plasma level of AGEs in patients with Wagner grade 0 diabetic foot ulcers of blood stasis or/and kidney yang deficiency syndrome. Design, setting, participants and interventions: A random and positive control method was adopted. Seventy-two cases of Wagner classification of grade 0 diabetic foot ulcers with blood stasis or/and kidney yang deficiency syndrome were randomly divided into treatment group and control group. There were thirtysix cases in each group. All the patients were collected from Maoming Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine. Patients received oral and written information about the clinical procedures before giving their written informed consent. The study was approved by the Ethics Committee of Maoming Hospital of Traditional Chinese Medicine. The patients in the treatment group were treated with modified Danggui Sini Decoction, and the patients in the control group were treated with cilostazol. A course of treatment was 14 days, and the patients in the two groups were treated for 3 courses. Main outcome measures: The changes of clinical symptoms, ankle-brachial index (ABI), electromyography, lower extremity arteries measured by ultrasonic Doppler, fasting blood glucose, hemoglobin Alc, fibrinogen, and plasma level of AGEs were detected in the two groups before and after treatment. The safety of modified Danggui Sini Decoction was assessed by laboratory data and adverse events. Results: There were statistical differences in clinical efficacy, ABI, lower extremity arteries hemodynamics, and nerve conduction velocity between the two groups (P〈0.05, P〈0.01). The plasma level of AGEs after treatment was significantly decreased in the two groups, and the level of AGEs in the treatment group was lower than that in the control group (P〈0.05). Conclusion: Modified Danggui Sini Decoction can improve clinical symptoms in patients with diabetic foot ulcers of Wagner grade 0 and it shows therapeutic effects on diabetes complicated with vascular diseases.
出处 《中西医结合学报》 CAS 2009年第7期622-628,共7页 Journal of Chinese Integrative Medicine
关键词 糖尿病足 Wagner0级 当归四逆汤 糖基化终产物 随机对照试验 diabetic foot Wagner grade 0 Danggui Sini Decoction glycosylation end products randomizedcontrolled trial
  • 相关文献

参考文献14

  • 1Boulton AJ.The diabetic foot:a global view.Diabetes Metab Res Rev.2000; 16(1):S2-S5.
  • 2Fryberg RG.Diabetic foot ulcerations:management and adjunctive therapy.Clin Podiatr Med Surg.2003; 20 (4):709-728.
  • 3曾文和,赖国民,甘尔惠.糖尿病足截肢危险因素分析[J].中国糖尿病杂志,2002,10(4):252-253. 被引量:44
  • 4Jensen LJ,Stergaard J,Flyvbjerg A.AGE-RAGE and AGE cross-link interaction:important players in the pathogenesis of diabetic kidney disease.Horm Metab Res.2005; 37(1):26-34.
  • 5World Health Organization.Definition,diagnosis and classification of diabetes mellitus and its complication,report of a WHO consultation.1999:1.
  • 6许樟荣.糖尿病足病变的分类与诊治进展[J].内科急危重症杂志,2002,8(1):32-35. 被引量:105
  • 7Basta G,Schmidt AM,De Caterina R.Advanced glycation end products and vascular inflammation:implications for accelerated atherosclerosis in diabetes.Cardiovase Res.2004; 63(4):582-592.
  • 8Enomoto M,Adachi H,Yamagishi S,Takeuchi M,Furuki K,Hino A,Hiratsuka A,Takajo Y,Imaizumi T.Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans.Metabolism.2006; 55(7):912-917.
  • 9Forbes JM,Yee LT,Thallas V,Lassila M,Candido R,Jandeleit-Dahm KA,Thomas MC,Burns WC,Deemer EK,Thorpe SR,Cooper ME,Allen TJ.Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.Diabetes.2004; 53 (7):1813-1823.
  • 10Basra G,Lazzerini G,Del Turco S,Ratto GM,Schmidt AM,De Caterina R.At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products.Arterioscler Thromb Vasc Biol.2005; 25(7):1404-1407.

二级参考文献22

  • 1葛勇,张家庆,周云平.水飞蓟宾及槲皮素对体外白蛋白非酶糖化的抑制作用[J].第二军医大学学报,1995,16(4):333-336. 被引量:33
  • 2中国中西医结合学会周围血管疾病专业委员会.闭塞性周围血管病诊断及疗效标准[J].临床荟萃,1990,5:39-41.
  • 3美国糖尿病学会.国际专家委员会Diabetes Care[S].,1997,2.1183.
  • 4[1]Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis andoutpatientt ,amagement of diabetic peripheral neuropathy. Diabet Med, 1998, 15:508.
  • 5[2]Boulton AJ. Foot problems in patients with diabetes mellitus. In: Pickup J, Williams G, eds. Textbook of Diabetes. 2ncl ed. London: Blackwell, 1997, 58:1.
  • 6[3]Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care, 1998, 21:855.
  • 7[4]American Diabetes Association. Consensus development conference on diabetic foot wound care. Diabetes Care, 1999, 22:1354.
  • 8[5]McGill M, Molyneaux L, Spencer R, et al. Possible sources of discrepancies in the use of the Smmes-Weinstein monofilament: Im pact on prevalence of irtsensate foot and workload requirements. Diabetes Care, 1999, 22:598.
  • 9[6]Armstrong DG. Infra-red dermal thermometry: a stethoscope for the diabetic foot? Forum on wound care, 1998, Special edition: 15.
  • 10[7]Barnett S. Gait analysis: part of the first national unified podiatry conference. Diabetic Foot, 1998, 1:72.

共引文献200

同被引文献281

引证文献14

二级引证文献184

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部